FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
![]() |
Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from Alzheimer's Disease[1]
SYDNEY, Dec. 22, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2...
Read more: FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial





